相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Broadly neutralizing antibodies against HIV-1 and concepts for application
Henning Gruell et al.
CURRENT OPINION IN VIROLOGY (2022)
HIV cure trial mergers: Spotlighting the epigenetics of latency reversal
Paul W. Denton
EBIOMEDICINE (2022)
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies
Rachel L. Rutishauser et al.
CURRENT OPINION IN HIV AND AIDS (2022)
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
Arshpreet Kaur et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2022)
The role of latency reversal in HIV cure strategies
Kiho Tanaka et al.
JOURNAL OF MEDICAL PRIMATOLOGY (2022)
Immunopotentiation by linking Hsp70 T-cell epitopes to Gag-Pol-Env-Nef-Rev multiepitope construct and increased IFN-gamma secretion in infected lymphocytes
Elahe Akbari et al.
PATHOGENS AND DISEASE (2022)
Immunological approaches to HIV cure
Adam R. Ward et al.
SEMINARS IN IMMUNOLOGY (2021)
The Emerging Role for CTL Epitope Specificity in HIV Cure Efforts
Clarety Kaseke et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?
Daniel C. Rogan et al.
CURRENT HIV/AIDS REPORTS (2021)
Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review
Ronald Derking et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2021)
HIV mRNA Vaccines-Progress and Future Paths
Zekun Mu et al.
VACCINES (2021)
In silico design and in vitro expression of novel multiepitope DNA constructs based on HIV-1 proteins and Hsp70 T-cell epitopes
Elahe Akbari et al.
BIOTECHNOLOGY LETTERS (2021)
Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines
Edmund G. Wee et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)
The current and future role of nanovaccines in HIV-1 vaccine development
Christopher P. Karch et al.
EXPERT REVIEW OF VACCINES (2021)
Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations
Lu Zheng et al.
CURRENT HIV/AIDS REPORTS (2021)
Current Status of HIV-1 Vaccines
Anna Hargrave et al.
VACCINES (2021)
Unified model of short- and long-term HIV viral rebound for clinical trial planning
Jessica M. Conway et al.
JOURNAL OF THE ROYAL SOCIETY INTERFACE (2021)
Advances toward Curing HIV-1 Infection in Tissue Reservoirs
Lisa J. Henderson et al.
JOURNAL OF VIROLOGY (2020)
T cell-based strategies for HIV-1 vaccines
Bette Korber et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy
Sonia Moretti et al.
EXPERT REVIEW OF VACCINES (2020)
Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges
Punnee Pitisuttithum et al.
EXPERT REVIEW OF VACCINES (2020)
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
Sarah Fidler et al.
LANCET (2020)
Comparative analysis of two HIV-1 multiepitope polypeptides for stimulation of immune responses in BALB/c mice
Kimia Kardani et al.
MOLECULAR IMMUNOLOGY (2020)
Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
Amina Ait-Ammar et al.
FRONTIERS IN MICROBIOLOGY (2020)
Novel Approaches Towards a Functional Cure of HIV/AIDS
Lucia Bailon Alvarez et al.
DRUGS (2020)
Therapeutic Vaccines for the Treatment of HIV
Zhilin Chen et al.
TRANSLATIONAL RESEARCH (2020)
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
Miriam Posas-Umbert et al.
FRONTIERS IN IMMUNOLOGY (2020)
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Beatriz Mothe et al.
FRONTIERS IN IMMUNOLOGY (2020)
Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission
Jesper Damsgaard Gunst et al.
CURRENT OPINION IN HIV AND AIDS (2020)
CD8+ T cells in HIV control, cure and prevention
David R. Collins et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption
Juergen K. Rockstroh et al.
PLOS ONE (2019)
Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
Nathifa Moyo et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination
Mathieu Surenaud et al.
PLOS PATHOGENS (2019)
Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
Tomas Hanke
EXPERT REVIEW OF VACCINES (2019)
Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix
Wesley de Jong et al.
VACCINES (2019)
The Safety and Immunogenicity of GTU®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART
G. Haidari et al.
FRONTIERS IN IMMUNOLOGY (2019)
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
Beatriz Mothe et al.
ECLINICALMEDICINE (2019)
CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication
Hayato Murakoshi et al.
RETROVIROLOGY (2018)
Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies
Nabila Seddiki et al.
CURRENT OPINION IN HIV AND AIDS (2018)
Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection
Lorna Leal et al.
AIDS (2018)
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
Erica N. Borducchi et al.
NATURE (2018)
Antibody-mediated prevention and treatment of HIV-1 infection
Henning Gruell et al.
RETROVIROLOGY (2018)
New challenges in therapeutic vaccines against HIV infection
Lorna Leal et al.
EXPERT REVIEW OF VACCINES (2017)
Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs
G. Tapia et al.
JOURNAL OF INFECTION (2017)
Vaccine nanoparticles for protection against HIV infection
Marisa E. Aikins et al.
NANOMEDICINE (2017)
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey et al.
NATURE MEDICINE (2017)
Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection
Matthew S. Parsons et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
Gemma Hancock et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2017)
The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
Kristin Brekke et al.
BMC INFECTIOUS DISEASES (2017)
HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine
Gina M. Graziani et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection
Beatrice Ondondo et al.
MOLECULAR THERAPY (2016)
Perspectives for immunotherapy: which applications might achieve an HIV functional cure?
Vincent Vieillard et al.
ONCOTARGET (2016)
Combined eff ect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
Steffen Leth et al.
LANCET HIV (2016)
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults
Gaudensia Mutua et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques
Beatriz Mothe et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes
Hayato Murakoshi et al.
JOURNAL OF VIROLOGY (2015)
Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides
Melissa C. Hanson et al.
VACCINE (2015)
Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development
Alena Y. Reguzova et al.
EXPERT REVIEW OF VACCINES (2015)
Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines
Tomas Hanke
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial
Richard B. Pollard et al.
LANCET INFECTIOUS DISEASES (2014)
Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1
Nicola Borthwick et al.
MOLECULAR THERAPY (2014)
Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial
Emma-Jo Hayton et al.
PLOS ONE (2014)
Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial
Kristin Brekke et al.
PLOS ONE (2014)
Immunologic strategies for HIV-1 remission and eradication
Dan H. Barouch et al.
SCIENCE (2014)
Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau
Victor Raul Gomez Roman et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2013)
Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection
Ingrid Karlsson et al.
CLINICAL IMMUNOLOGY (2013)
Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial
Marta Boffito et al.
VACCINE (2013)
Synthetic immunotherapy induces HIV virus specific Th1 cytotoxic response and death of an HIV-1 infected human cell line through classic complement activation
Olga Pleguezuelos et al.
VIROLOGY JOURNAL (2013)
HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia
Gideon Goldstein et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naive and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects
Gideon Goldstein et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine
Amanda Cobb et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Definition of the viral targets of protective HIV-1-specific T cell responses
Beatriz Mothe et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01
Anders Fomsgaard et al.
VACCINE (2011)
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
Dominique Salmon-Ceron et al.
AIDS (2010)
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques
Maximillian Rosario et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting
Gideon Goldstein et al.
VACCINE (2010)
Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control
Adam R. Hersperger et al.
PLOS PATHOGENS (2010)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8+ Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice
Gregers Jacob Gram et al.
PLOS ONE (2009)
Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
Sven Letourneau et al.
PLOS ONE (2007)
HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/FN-γ-secreting CD4+ and CD4+/CD8+ T cells in humans after lipopeptide vaccination
Hanne Gahery et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide-vaccine:: Characterization of CD8+-T-cell epitopes recognized
H Gahéry-Ségard et al.
JOURNAL OF VIROLOGY (2003)
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
EM Janssen et al.
NATURE (2003)
分享论文
